Avant Sciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Avant Sciences is a private, preclinical-stage biotech focused on revolutionizing retinal surgery through its proprietary evaporative tamponade platform. The company's lead program, evapRET, is in GMP production and in vivo pre-IDE testing, with three other pipeline candidates (EOD-2, EOD-3, EOD-4) in various stages of preclinical development. Led by a clinician-founder with deep expertise in vitreoretinal surgery and supported by a seasoned team of ophthalmology experts, the company is advancing towards regulatory milestones while presenting data at major medical conferences. Avant Sciences is currently pre-revenue and appears to be funded by a seed round closed in September 2023.

OphthalmologyRetinal Diseases

Technology Platform

Proprietary platform for developing first-in-class evaporative retinal tamponades designed to dissipate after use, eliminating the need for surgical removal. Augmented by computational models for formulation discovery.

Opportunities

The evaporative tamponade addresses a clear unmet need by eliminating a second removal surgery, which could reduce overall healthcare costs and improve patient quality of life, creating a strong value proposition.

The aging population and rising prevalence of retinal diseases provide a growing market for innovative surgical aids.

The company's strong clinical and academic foundation facilitates credibility with key opinion leaders and potential strategic partners in ophthalmology.

Risk Factors

The novel evaporative mechanism carries technical risk; it must be proven safe, predictable, and non-inflammatory in human eyes.

As a first-in-class device, it faces a potentially complex and lengthy regulatory pathway with the FDA.

Market adoption may be slow as it requires surgeons to change established surgical protocols, and large incumbent device companies could develop competing solutions.

Competitive Landscape

Avant Sciences competes in the retinal tamponade market, currently dominated by established products like silicone oil and intraocular gases (e.g., from Alcon, Bausch + Lomb). Its primary competition is the standard of care itself, which is effective but requires removal surgery. Other companies may be developing improved tamponades or sustained-release drug delivery systems, but a purely evaporative tamponade appears to be a unique approach, positioning Avant in a potentially novel niche.

More companies in Diagnostics & Precision Medicine →More companies in United States →